Retention in buprenorphine treatment is associated with improved HCV care outcomes

• Published in: Journal of substance abuse treatment 2017-04, Vol.75, p.38-42
• Main Authors: Norton, BL, Beitin, A, Glenn, M, DeLuca, J, Litwin, AH, Cunningham, CO
• Format: Article
• Language: English
• Subjects: Adult; Buprenorphine; Buprenorphine - administration & dosage; Cascade of care; Clinical outcomes; Computerized medical records; Drug abuse; Female; Health records; Hepatitis; Hepatitis Antibodies - blood; Hepatitis C; Hepatitis C - complications; Hepatitis C - drug therapy; Hepatitis C - epidemiology; Hepatitis C - virology; Humans; Infections; Male; Medical treatment; Medication assisted treatment; Middle Aged; Morbidity; Morbidity-Mortality; Mortality; Narcotics; New York City - epidemiology; Opiate Substitution Treatment; Opioid use disorder; Opioid-Related Disorders - complications; Opioid-Related Disorders - rehabilitation; Patient Compliance; Patients; Primary care; Psychiatry; Retention; Substance abuse treatment; Treatment Outcome; Viral infections
• ISSN: 0740-5472; 1873-6483
• DOI: 10.1016/j.jsat.2017.01.015

Abstract Persons who inject drugs, most of whom are opioid dependent, comprise the majority of the HCV infected in the United States. As the national opioid epidemic unfolds, increasing numbers of people are entering the medical system to access treatment for opioid use disorder, specifically with buprenorphine. Yet little is known about HCV care in patients accessing buprenorphine-based opioid treatment. We sought to determine the HCV prevalence, cascade of care, and the association between patient characteristics and completion of HCV cascade of care milestones for patients initiating buprenorphine treatment. We reviewed electronic health records of all patients who initiated buprenorphine treatment at a primary-care clinic in the Bronx, NY between January 2009 and January 2014. Of the 390 patients who initiated buprenorphine treatment, 123 were confirmed to have chronic HCV infection. The only patient characteristic associated with achieving HCV care milestones was retention in opioid treatment. Patients retained (vs. not retained) in buprenorphine treatment were more likely to be referred for HCV specialty care (63.1% vs. 34.0%, p < 0.01), achieve an HCV-specific evaluation (40.8% vs. 21.3%, p < 0.05), be offered HCV treatment (22.4% vs. 8.5%, p < 0.05), and initiate HCV treatment (9.2% vs. 6.4%, p = 0.6). Given the current opioid epidemic in the US and the growing number of people receiving buprenorphine treatment, there is an unprecedented opportunity to access and treat persons with HCV, reducing HCV transmission, morbidity and mortality. Retention in opioid treatment may improve linkage and retention in HCV care; innovative models of care that integrate opioid drug treatment with HCV treatment are essential.